1. ¹Cancer Research UK, Epidemiology Unit, Gibson Building, Radcliffe Infirmary, Oxford OX2 6HE, UK
2. ²Uganda Cancer Institute and Makerere University Medical School, Kampala, Uganda
3. ³Cancer Research UK, Viral Oncology Group, Wolfson Institute of Medical Sciences, Cruciform Building, Gower Street, London WC1E 6BT, UK
4. ⁴MRC Programme on AIDS, Uganda Virus Research Institute, PO Box 49, Entebbe, Uganda
5. ⁵International Agency for Research on Cancer, 150 Cours Albert Thomas, Lyon, France
6. ⁶Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, Georgia, 30333, USA
7. ⁷Windeyer Institute, University College London, 46 Cleveland Street, London, UK

Correspondence: Dr R Newton, E-mail: rob.newton@cancer.org.uk

⁸JZ was on secondment from the Department of Veterans Affairs and the University of California, San Francisco, to the International Agency for Research on Cancer, France

⁹LC was on secondment from the Academic Department of Public Health, Oxford University, to the MRC Programme on AIDS, Entebbe, Uganda

Received 6 January 2003; Revised 2 May 2003; Accepted 7 May 2003.

Abstract

A case–control study from Uganda found that the risk of Kaposi's sarcoma increased with increasing titre of antibodies against Kaposi's sarcoma-associated herpesvirus (KSHV) latent nuclear antigens, independently of HIV infection. Clinically, widespread Kaposi's sarcoma was more frequent among patients with HIV infection than in those without, but was not related to anti-KSHV antibody titres.